TNF and type 2 diabetes mellitus: In the PREDIAN trial, patients with T2DM and CKD (stages 3–4) were treated with pentoxifylline in addition to RAAS inhibitors for 2 years, resulting in a smaller decrease in eGFR and greater reduction of residual albuminuria, coinciding with a marked reduction in urinary TNF-α [146].